Risk Management: What Regulatory Professionals Need to Know
- Published on February 25, 2013
- Written by Mike McClain, Senior Web Designer & Site Manager
RAPS’ latest publication covers the theory and application of risk management principles as they relate to the development and approval of drugs and medical devices. The 145-page publication, Risk Management Principles for Devices and Pharmaceuticals: Global Perspectives on the Benefit: Risk Assessment of Medicinal Products, features 16 chapters written by 29 regulators, contractors, academics and global industry experts, representing organizations including the US Food and Drug Administration, Eli Lilly and Company, Bayer Pharma, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) and others.